![]()
|
|
||||||||
J. Biol. Chem., Vol. 281, Issue 2, 1286-1295, January 13, 2006
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1
2
23
4
5
From the
Genome Damage and Stability Centre, University of Sussex, Falmer, Brighton BN1 9RQ, United Kingdom, the
Medical Research Council Cancer Cell Unit, Hutchison/Medical Research Council Research Centre, Hills Road, Cambridge CB2 2XZ, United Kingdom, and the ¶University of California, San Diego, Ludwig Institute for Cancer Research, La Jolla, California 92093-0660
Survivin is a protein with proposed roles in cell division and apoptosis. Transcripts encoding splice variants of human survivin have been described and their expression correlated with cancer progression. As survivin forms homodimers in vitro, it has been suggested that these isoforms could interfere with wild type function by forming heterodimers. Here we show that survivin-2
and survivin-
Ex3 can interact with wild type survivin but have reduced affinity for the partner protein of survivin, borealin, and thus do not localize with the chromosomal passenger complex in vivo. Furthermore, we demonstrate that overexpression of survivin-2
-green fluorescent protein (GFP) or survivin-
Ex3-GFP does not impede cell cycle progression. We also report that wild type survivin, but not survivin-2
-GFP or survivin-
Ex3-GFP, can rescue cell proliferation inhibited by small interfering RNA-mediated survivin depletion. These data suggest that, despite their ability to interact with wild type survivin, neither of these isoforms acts as its competitor during mitosis nor has an essential function.
Received for publication, August 9, 2005 , and in revised form, November 2, 2005.
* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 Supported in part by a post-doctoral Human Frontier Science Program Fellowship.
2 These authors contributed equally to this work.
3 Holds a Medical Research Council (MRC) studentship.
4 Work in the laboratory of P. K. F. was supported by a grant-in-aid to the MRC Cancer Cell Unit.
5 A Cancer Research-UK Senior Fellow. To whom correspondence should be addressed. Tel.: 44-1273-873431; Fax: 44-1273-678121; E-mail: s.p.wheatley{at}sussex.ac.uk.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
C. M. Connell, R. Colnaghi, and S. P. Wheatley Nuclear Survivin Has Reduced Stability and Is Not Cytoprotective J. Biol. Chem., February 8, 2008; 283(6): 3289 - 3296. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Pennati, M. Folini, and N. Zaffaroni Targeting survivin in cancer therapy: fulfilled promises and open questions Carcinogenesis, June 1, 2007; 28(6): 1133 - 1139. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Colnaghi, C. M. Connell, R. M. A. Barrett, and S. P. Wheatley Separating the Anti-apoptotic and Mitotic Roles of Survivin J. Biol. Chem., November 3, 2006; 281(44): 33450 - 33456. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Wolanin, A. Magalska, G. Mosieniak, R. Klinger, S. McKenna, S. Vejda, E. Sikora, and K. Piwocka Curcumin Affects Components of the Chromosomal Passenger Complex and Induces Mitotic Catastrophe in Apoptosis-Resistant Bcr-Abl-Expressing Cells Mol. Cancer Res., July 1, 2006; 4(7): 457 - 469. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |